

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF
AUSBORN ET AL.

INTERNATIONAL APPLICATION NO: PCT/EP03/13776

FILED: 5 DECEMBER 2003

U.S. APPLICATION NO: 10/537,038

35 USC §371 DATE: 21 NOVEMBER 2005

FOR: MICROPARTICLES PREPARED USING AN IONIC LIQUID

MS: Amendment

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:


This paper is supplemental to the Information Disclosure Statement filed June 1, 2005. Since Applicants believe this paper is being filed before the mailing date of a first Office Action on the merits, no fees are believed to be required under 37 C.F.R. §1.97(b)(3). If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Novartis Pharmaceuticals Corp.
Patents Pharma
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(862) 778-7877



John W. Kung
Attorney for Applicants
Reg. No. 44,199

Date: *Aug. 11, 2008*